ANI Pharmaceuticals price target raised to $86 from $84 at Raymond James

Raymond James analyst Gary Nachman raised the firm’s price target on ANI Pharmaceuticals (ANIP) to $86 from $84 and keeps an Outperform rating on the shares. ANI’s Q1 had solid top- and bottom-line beats driven mostly by Generics leading to another guidance raise early in the year, and in Rare Disease, Cortrophin fundamentals are strong and Iluvien and Yutiq near-term headwinds are being managed, the analyst tells investors in a research note. ANI also stressed it should be well insulated from tariff concerns given its U.S. based manufacturing, the firm notes.